Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q3 2023 Earnings Conference Call November 2, 2023 5:00 PM ET

Company Participants

Christine Cassiano – Chief Corporate Affairs and Brand Strategy Officer

David Chang – President and Chief Executive Officer

Zachary Roberts – Executive Vice President of Research and Development and Chief Medical Officer

Geoff Parker – Chief Financial Officer

Conference Call Participants

Michael Yee – Jefferies

Tyler Van Baron – TD Cowen

Brian Cheng – JPMorgan

Jack Allen – Baird

Kelsey Goodwin – Guggenheim Securities

John Newman – Canaccord Genuity

Andy Fleszar – B. Riley

Sami Corwin – William Blair

Hartaj Singh – Oppenheimer

Operator

Hello, and thank you for standing by. Welcome to the Allogene Therapeutics Third Quarter 2023 Conference Call. After the speakers’ presentation, there will be a question-and-answer session. [Operator Instructions] Please be aware that today’s conference is being recorded.

I would now like to turn the call over to Christine Cassiano, Chief Corporate Affairs and Brand Strategy Officer. Ms. Cassiano, please go ahead.

Christine Cassiano

Thank you, operator, and welcome to our call. Today, after market closed, Allogene issued a press release that provides a business update and financial results for the third quarter of 2023. This press release and today’s webcast are both available on our website. Following our prepared remarks, we will host a Q&A session. We ask you to limit your questions to one per person as we will keep this call to an hour and do our best to get to as many questions as possible.

Joining me today are Dr. David Chang, President and Chief Executive Officer; Dr. Zachary Roberts, Executive Vice President of Research and Development and Chief Medical Officer; and Geoff Parker, Chief Financial Officer.

During today’s call, we will be making certain forward-looking statements. These may include statements regarding the success and timing of our ongoing and planned clinical trials, data presentations, regulatory filings, future research and development efforts, manufacturing capabilities, the safety and efficacy of any of our product candidate, and 2023 financial guidance, among other things. These forward-looking statements are based on current information, assumptions and expectations that are subject to change. A description of potential risks can be found in our earnings press release and the latest SEC disclosure documents. You are cautioned not to place undue reliance on these forward-looking statements and Allogene disclaims any obligation to update these statements.

I’ll now turn the call over to David.